Trial Profile
Integrating intravenous oxaliplatin plus oral capecitabine with pelvic radiation for rectal cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Aug 2005
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Rectal cancer
- Focus Adverse reactions
- 01 Aug 2005 New trial record.